会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Process for the preparation of pyrimidine derivatives
    • 制备嘧啶衍生物的方法
    • US20050124639A1
    • 2005-06-09
    • US11004755
    • 2004-12-03
    • Narendra JoshiShekhar BhirudBatchu ChandrasekharK. RaoSubhash Damle
    • Narendra JoshiShekhar BhirudBatchu ChandrasekharK. RaoSubhash Damle
    • C07D239/42A61K31/513A61K31/505C07D239/34
    • C07D239/42Y02P20/55
    • An improved process for the preparation of pyrimidine derivatives is provided comprising reacting a Wittig reagent of the general formula wherein R is an alkyl of from 1 to 10 carbon atoms, aryl or arylalkyl, R1 is a substituted or unsubstituted hydrocarbon group, R2 and R3 are the same or different and are hydrogen or a substituted or unsubstituted hydrocarbon group; Z is sulfur, oxygen, sulfonyl, or imino which may be substituted by formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, amino substituted by sulfonyl or alkylsulfonyl, and sulfonyl substituted by alkyl, amino or alkylamino and X is a halogen; with an aldehyde of the general formula wherein R4 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt and each R5 are the same or different and are hydrogen or a hydrolyzable protecting group, or each R5, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R5 is bonded to the same substituent which is bonded to each oxygen atom to form a hydrolyzable protecting group; in the presence of a base.
    • 提供了制备嘧啶衍生物的改进方法,包括使通式为Wittig试剂反应其中R为1至10个碳原子的烷基,芳基或芳基烷基,R 1是被取代或 未取代的烃基,R 2和R 3相同或不同,为氢或取代或未取代的烃基; Z可以被甲酰基,乙酰基,丙酰基,丁酰基,异丁酰基,戊酰基,异戊酰基,被磺酰基或烷基磺酰基取代的氨基,和被烷基,氨基或烷基氨基取代的磺酰基取代的硫,氧,磺酰基或亚氨基,X是卤素 ; 与其中R 4为氢的通式的醛,能够形成无毒的药学上可接受的盐的低级烷基或阳离子和每个R 5相同 或不同的是氢或可水解保护基团,或每个R 5与每个键合的氧原子一起形成可水解的环保护基团,或每个R 5, SUP>键合到与每个氧原子键合的相同取代基以形成可水解保护基团; 在一个基地的存在。
    • 2. 发明授权
    • Process for the preparation of pyrimidine derivatives
    • 制备嘧啶衍生物的方法
    • US07312329B2
    • 2007-12-25
    • US11004755
    • 2004-12-03
    • Narendra JoshiShekhar Bhaskar BhirudBatchu ChandrasekharK. Eswara RaoSubhash Damle
    • Narendra JoshiShekhar Bhaskar BhirudBatchu ChandrasekharK. Eswara RaoSubhash Damle
    • C07F9/02C07D239/02
    • C07D239/42Y02P20/55
    • An improved process for the preparation of pyrimidine derivatives is provided comprising reacting a Wittig reagent of the general formula wherein R is an alkyl of from 1 to 10 carbon atoms, aryl or arylalkyl, R1 is a substituted or unsubstituted hydrocarbon group, R2 and R3 are the same or different and are hydrogen or a substituted or unsubstituted hydrocarbon group; Z is sulfur, oxygen, sulfonyl, or imino which may be substituted by formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, amino substituted by sulfonyl or alkylsulfonyl, and sulfonyl substituted by alkyl, amino or alkylamino and X is a halogen; with an aldehyde of the general formula wherein R4 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt and each R5 are the same or different and are hydrogen or a hydrolyzable protecting group, or each R5, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R5 is bonded to the same substituent which is bonded to each oxygen atom to form a hydrolyzable protecting group; in the presence of a base.
    • 提供了制备嘧啶衍生物的改进方法,包括使通式为Wittig试剂反应其中R为1至10个碳原子的烷基,芳基或芳基烷基,R 1是被取代或 未取代的烃基,R 2和R 3相同或不同,为氢或取代或未取代的烃基; Z可以被甲酰基,乙酰基,丙酰基,丁酰基,异丁酰基,戊酰基,异戊酰基,被磺酰基或烷基磺酰基取代的氨基,和被烷基,氨基或烷基氨基取代的磺酰基取代的硫,氧,磺酰基或亚氨基,X是卤素 ; 与其中R 4为氢的通式的醛,能够形成无毒的药学上可接受的盐的低级烷基或阳离子和每个R 5相同 或不同的是氢或可水解保护基团,或每个R 5与每个键合的氧原子一起形成可水解的环保护基团,或每个R 5, SUP>键合到与每个氧原子键合的相同取代基以形成可水解保护基团; 在一个基地的存在。
    • 3. 发明申请
    • Processes for the preparation of simvastatin
    • 辛伐他汀的制备方法
    • US20050239885A1
    • 2005-10-27
    • US11112893
    • 2005-04-22
    • Narendra JoshiShekhar BhirudKodali Rao
    • Narendra JoshiShekhar BhirudKodali Rao
    • A61K31/225C07C67/02C07C211/63
    • C07D309/30C07C211/63
    • Improved processes for the preparation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitors, e.g., simvastatin, and their intermediates are provided. In one embodiment, a process for the preparation of a carboxylic acid amine salt of formula I is provided wherein R1 and R2 are as defined herein, the process comprising reacting lovastatin with an amine of formula III: in an aqueous medium to provide the carboxylic acid amine salt of formula I. The process further includes the steps of lithiating the carboxylic acid amine salt of formula I to form the corresponding 2,2-dimethylbutyrate intermediate of formula IIa lactonizing the 2,2-dimethylbutyrate intermediate (IIa) to provide simvastatin and pharmaceutically acceptable salts thereof. Also provided is an improved process for lactonization of the intermediates herein using peptide coupling reagents.
    • 提供了制备3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)抑制剂,例如辛伐他汀及其中间体的改进方法。 在一个实施方案中,提供了制备式I的羧酸胺盐的方法,其中R 1和R 2如本文所定义,所述方法包括使洛伐他汀 与式III的胺在水性介质中反应,得到式I的羧酸胺盐。该方法还包括将式I的羧酸胺盐锂化以形成相应的2,2-二甲基丁酸酯中间体 IIa将2,2-二甲基丁酸中间体(IIa)内酯化以提供辛伐他汀及其药学上可接受的盐。 还提供了使用肽偶联试剂使本文中间体内酯化的改进方法。
    • 8. 发明申请
    • Process for the preparation of angiotensin receptor blockers and intermediates thereof
    • 制备血管紧张素受体阻滞剂及其中间体的方法
    • US20060211866A1
    • 2006-09-21
    • US11386010
    • 2006-03-21
    • Narendra JoshiKodali RaoBuddhavarapu RamamShekhar Bhirud
    • Narendra JoshiKodali RaoBuddhavarapu RamamShekhar Bhirud
    • C07D403/02C07D235/04
    • C07D257/04C07D235/20C07D403/10
    • A process for the preparation of a biphenyl-containing compound of general formula I: wherein R1 is a C3-6 carbonyl containing compound; R2 is a substituted or unsubstituted, straight or branched C3-6 alkyl group, or R1 and R2 together with the nitrogen atom to which they are bonded are joined together to form a substituted heterocyclic group selected from the group consisting of substituted or unsubstituted imidazoles, substituted or unsubstituted benzimidazoles and substituted or unsubstituted 1,3-diazaspiro[4,4]non-1-en-4-one; and R3 is a carboxylic acid ester, cyano, a substituted or unsubstituted 1H-tetrazolyl group or a substituted or unsubstituted group which may be converted in vivo into a carboxy group is provided, the process comprising reacting a compound of general formula II: wherein R1 and R2 have the aforestated meanings with a compound of general formula III: wherein Z is a leaving group and R3 has the aforestated meaning in a biphasic solvent system in the presence of a phase transfer catalyst.
    • 一种制备含联苯的通式I化合物的方法:其中R 1是含3-6个碳原子的化合物; R 2是取代或未取代的直链或支链C 3-6 - 烷基,或R 1和R 2, SUP与它们所键合的氮原子一起连接在一起形成选自取代或未取代的咪唑,取代或未取代的苯并咪唑和取代或未取代的1,3-二氮杂螺[4,4] 非1-烯-4-酮; R 3是可以在体内转化为羧基的羧酸酯,氰基,取代或未取代的1H-四唑基或取代或未取代的基团,该方法包括使 通式II的化合物:其中R 1和R 2具有通式III的化合物的前述含义:其中Z是离去基团,R 3 在相转移催化剂存在下,在双相溶剂体系中具有上述含义。